Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6422-6424

  Sańchez Ortega, Isabel ^a,b   Vázquez, Lourdes ^c   Montes, Carmen ^d   Patiño, Beatriz ^a,e   Arnan, Montserrat ^a,e   Bermúdez, Arancha ^d   Yáñez, Lucrecia ^d   Caballero, Teresa ^c   Duarte, Rafael F ^a,e  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; POSACONAZOLE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPROPHYLAXIS; MALE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES; TRIAZOLES; YOUNG ADULT;

EID: 84869232458     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01489-12     Document Type: Article

References (20)

1. Applebaum FR, Forman SJ, Negrin RS, Blume KG. 2009. Pharmacologic prevention of acute graft-versus-host disease, p 1257-1274. In Applebaum FR, Forman SJ, Negrin RS, Blume KG (ed), Thomas' hematopoietic cell transplantation, 4th ed. Blackwell Publishing, Ltd., Oxford, United Kingdom.
2. Berge M, et al. 2009. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther. Drug Monit. 31:396-399.
3. Reference deleted.
4. Farowski F, Vehreschild JJ, Cornely OA. 2007. Posaconazole: a next-generation triazole antifungal. Future Microbiol. 2:231-243.
5. Ghalie R, Fitzsimmons WE, Weinstein A, Manson S, Kaizer H. 1994. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann. Pharmacother. 28:379-383.
6. Kanda Y, et al. 2006. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am. J. Hematol. 81:838-844.
7. Keating GM. 2005. Posaconazole. Drugs 65:1553-1567.
8. Kohl V, et al. 2010. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob. Agents Chemother. 54:207-212.
9. Kubiak DW, et al. 2012. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. Biol. Blood Marrow Transplant. 18:1462-1465.
10. Langston A, Lipton JH, Brundage T, Patinmo H, Ullmann AJ. 2007. Impact of posaconazole vs fluconazole on cyclosporine and tacrolimus dosing in hematopoietic stem cell transplant recipients with graft-versus-host disease. Biol. Blood Marrow Transplant. 13(Suppl. 2):76.
11. Malard F, et al. 2010. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 16:28-34.
12. Martin P, et al. 2003. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 32:777-784.
13. Moton A, et al. 2009. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr. Med. Res. Opin. 25:701-707.
14. Przepiorka D, et al. 1991. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant. 7:461-465.
15. Sánchez-Ortega I, et al. 2011. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant. 46:733-739.
16. Sansone-Parsons A, et al. 2007. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 27:825-834.
17. Schering Corporation. 2008. Prescribing information for Noxafil (posaconazole) oral suspension. Schering Corporation, Kenilworth, NJ.
18. Ullmann AJ, et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
19. Yee GC, et al. 1988. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N. Engl. J. Med. 319:65-70.
20. Zhuang D, et al. 2008. Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. Antimicrob. Agents Chemother. 52:730-731.